{
"id":"mk19_b_en_t43",
"number":43,
"bookId":"en",
"title":{
"__html":"Monitoring of Gender-Affirming Hormonal Therapy"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"2880c5",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 43. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t43"
}
]
},
"Monitoring of Gender-Affirming Hormonal Therapy"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"423e55",
"class":"col hd l",
"children":[
"Monitoring"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e1e4ae",
"class":"col hd l",
"children":[
"Male Transgender Patients"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2556ef",
"class":"col hd l",
"children":[
"Female Transgender Patients"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c00a2a",
"class":"cell txt l",
"children":[
"Frequency of follow-up",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d3fc04",
"class":"cell txt li",
"children":[
"Every 2-3 months during first year of treatment"
]
},
" ",
{
"type":"p",
"hlId":"c6d691",
"class":"cell txt li",
"children":[
"Every 6-12 months thereafter"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d3fc04",
"class":"cell txt li",
"children":[
"Every 2-3 months during first year of treatment"
]
},
" ",
{
"type":"p",
"hlId":"c6d691",
"class":"cell txt li",
"children":[
"Every 6-12 months thereafter"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"43c757",
"class":"cell txt l",
"children":[
"Clinical evaluation at each visit"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"771875",
"class":"cell txt li",
"children":[
"Blood pressure, weight, pulse"
]
},
" ",
{
"type":"p",
"hlId":"7973f0",
"class":"cell txt li",
"children":[
"Physical examination, including cardiopulmonary and skin examination"
]
},
" ",
{
"type":"p",
"hlId":"bb7c5c",
"class":"cell txt li",
"children":[
"Monitor for appropriate signs of virilization"
]
},
" ",
{
"type":"p",
"hlId":"ffd6a4",
"class":"cell txt li",
"children":[
"Monitor for adverse reactions, excess weight gain, acne, uterine breakthrough bleeding, and cardiovascular impairment, and for psychiatric symptoms in high-risk patients"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"771875",
"class":"cell txt li",
"children":[
"Blood pressure, weight, pulse"
]
},
" ",
{
"type":"p",
"hlId":"49f98f",
"class":"cell txt li",
"children":[
"Physical examination, including cardiopulmonary examination"
]
},
" ",
{
"type":"p",
"hlId":"bade76",
"class":"cell txt li",
"children":[
"Monitor for appropriate signs of feminization"
]
},
" ",
{
"type":"p",
"hlId":"068ac4",
"class":"cell txt li",
"children":[
"Monitor for adverse reactions; assess for signs of cardiovascular impairment and venous thromboembolism"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7ed28a",
"class":"cell txt l",
"children":[
"Laboratory evaluation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"782288",
"class":"cell txt li",
"children":[
"Testosterone: Every 2-3 months with titration to physiologic male range (350-700 ng/dL [12.1-24.3 nmol/L]); when at goal, measure every 6-12 months"
]
},
" ",
{
"type":"p",
"hlId":"ced1f5",
"class":"cell txt li",
"children":[
"Estradiol: Measure every 2-3 months until cessation of menstrual bleeding; goal is <50 pg/mL (183.5 pmol/L)"
]
},
" ",
{
"type":"p",
"hlId":"53b5a1",
"class":"cell txt li",
"children":[
"CBC and liver function before therapy initiation, every 3 months in first year, then every 6-12 months"
]
},
" ",
{
"type":"p",
"hlId":"b9be7e",
"class":"cell txt li",
"children":[
"Lipids: periodic monitoring"
]
},
" ",
{
"type":"p",
"hlId":"971cda",
"class":"cell txt li",
"children":[
"Fasting blood glucose and hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" in patients with personal or family history of diabetes mellitus"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"503f73",
"class":"cell txt li",
"children":[
"Testosterone: Measure every 2-3 months with goal <55 ng/dL (1.9 nmol/L)"
]
},
" ",
{
"type":"p",
"hlId":"f52557",
"class":"cell txt li",
"children":[
"Estradiol: Every 2-3 months with titration to physiologic female range; should not exceed peak physiologic range for young healthy women (ideal level <200 pg/mL [734 pmol/L]); when at goal, measure every 6-12 months"
]
},
" ",
{
"type":"p",
"hlId":"b0153f",
"class":"cell txt li",
"children":[
"Patients on spironolactone: monitor serum electrolytes (notably potassium) every 2-3 months during first year of therapy"
]
},
" ",
{
"type":"p",
"hlId":"602c70",
"class":"cell txt li",
"children":[
"Lipids, liver enzymes, and prolactin: periodic and individualized monitoring"
]
},
" ",
{
"type":"p",
"hlId":"f0c563",
"class":"cell txt li",
"children":[
"Fasting blood glucose and hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" in patients with a personal or family history of diabetes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"db7551",
"class":"cell txt l",
"children":[
"Screening"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de80e5",
"class":"cell txt li",
"children":[
"If cervical tissue is present, screen for cervical cancer as in nontransgender persons"
]
},
" ",
{
"type":"p",
"hlId":"7ead21",
"class":"cell txt li",
"children":[
"If breast tissue is present, screen for breast cancer with mammography as in nontransgender persons"
]
},
" ",
{
"type":"p",
"hlId":"98d695",
"class":"cell txt li",
"children":[
"Baseline bone mineral density testing if risk factors for osteoporosis are present; if low risk, screen for osteoporosis at age 60 years or younger in patients who stop taking hormone therapy after gonadectomy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5a8104",
"class":"cell txt li",
"children":[
"Routine cancer screening (colon, prostate) is recommended as in nontransgender persons"
]
},
" ",
{
"type":"p",
"hlId":"e8ca45",
"class":"cell txt li",
"children":[
"Consider baseline bone mineral density testing if risk factors for osteoporosis are present; if low risk, screen for osteoporosis at age 60 years or younger in patients who stop taking hormone therapy after gonadectomy"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Patients with comorbid medical conditions may need to be monitored more frequently."
],
[
"Data from Spack NP. Management of transgenderism. JAMA. 2013;309:478-84. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/23385274",
"target":"_blank"
},
"children":[
"PMID: 23385274"
]
},
" doi:10.1001/jama.2012.165234"
]
]
}